If you are an Ashkenazi Jewish man, it is understandable to question whether your heritage affects your prostate cancer risk. While this background does not mean you will develop the condition, certain inherited genetic changes are more commonly seen in this population. These variations can influence your overall level of risk.
Ashkenazi Jewish ancestry is relevant mainly because certain harmful BRCA1 and BRCA2 variants are more common in this population. Ancestry alone does not mean that you carry one of these variants or that you will develop prostate cancer.
Prostate cancer risk is influenced by several factors. Age, family history and certain inherited genetic variants are established prostate cancer risk factors. Body weight may be associated with the risk of advanced disease, while healthy habits primarily support your general health rather than removing inherited risk.
For some men, inherited pathogenic variants can also affect how prostate cancer behaves. In certain cases, the disease may be more aggressive or require closer monitoring. This is why understanding your genetic background and family history can help guide more personalised care.
The Importance of BRCA1 and BRCA2 Genes
BRCA1 and BRCA2 are genes that help repair damaged DNA and keep your cells functioning properly. When these genes work as they should, they reduce the risk of harmful cell changes. If you inherit a pathogenic variant, your body may be less effective at repairing certain types of DNA damage.
Although pathogenic BRCA variants are often associated with breast and ovarian cancer, they are also important for you as a man. These genetic changes can still affect how your cells grow and divide. This means your risk of developing certain cancers, including prostate cancer, may be higher.
The association with prostate cancer is strongest for harmful BRCA2 variants. BRCA2 carriers may have a higher likelihood of developing prostate cancer at a younger age and of developing clinically significant or more aggressive disease. The association with BRCA1 is less clear and appears to be smaller, so screening recommendations are not necessarily the same for the two genes.
Why Some Ashkenazi Jewish Men May Have Increased Genetic Risk
If you are of Ashkenazi Jewish heritage, you may carry inherited variants that are more common in this population. Some of these are known as founder variants. They arose in earlier generations and became more common because of historical population patterns before being passed down through families. As a result, harmful BRCA1 and BRCA2 variants are found more frequently in people of Ashkenazi Jewish ancestry than in the general UK population.
It is important to understand that not every Ashkenazi Jewish man carries one of these pathogenic variants. Even if a pathogenic variant is present, it does not mean you will definitely develop prostate cancer. However, it may increase your overall level of risk.
By identifying whether you carry these genetic changes, you can take a more personalised approach to your health. This may include earlier PSA discussions, tailored testing or more regular monitoring. Being aware of your genetic background can help you make more informed decisions about your care. NHS England reports that around 1 in 40 people of Ashkenazi Jewish ancestry carries a harmful BRCA variant, although most people do not carry one.
How Family History Influences Your Prostate Cancer Risk
Your family history can provide important insight into your risk of prostate cancer. If your father, brother or another close relative has been diagnosed, particularly at a younger age, your own risk may be higher. This may mean you would benefit from a more personalised assessment.
It is not only prostate cancer that matters when looking at your family history. A history of breast, ovarian or pancreatic cancer, or several cancers within your family, may suggest an inherited genetic risk. These patterns can sometimes indicate shared pathogenic variants.
Sharing your family history with your healthcare team can help guide decisions about genetic testing, individual PSA testing and appropriate follow-up. This supports a more personalised approach based on your family history and current guidance.
When Should You Consider Genetic Testing?
Genetic testing may be recommended if you have a strong family history of prostate or related cancers, a known pathogenic variant in your family, or prostate cancer that meets current NHS genomic-testing criteria. Germline genetic testing usually involves a blood or saliva sample. However, deciding whether testing is appropriate and understanding a positive, negative or uncertain result can be complex, which is why genetic counselling or specialist support may be helpful.
As of July 2026, the NHS Jewish BRCA Testing Programme is closed to new registrations following completion of its three-year pilot. NHS England is developing a longer-term service anticipated to open for new registrations in 2027. In the meantime, you may qualify for NHS testing through another pathway if you have a relative with a pathogenic BRCA variant or Jewish ancestry alongside a personal or family history of breast, ovarian or prostate cancer. Speak with your GP or an NHS genetics service for individual advice.
Considerations for Genetic Testing
| Situation | Who It Applies To | What It Involves | Why It Matters |
| Strong family history of cancer | Men with a pattern of prostate, breast, ovarian or pancreatic cancer in close relatives, particularly cancers diagnosed at a younger age, or a known pathogenic variant in the family | Discussion with a specialist and possible referral for testing | Helps identify inherited risk and guide earlier monitoring |
| Prostate cancer with qualifying clinical or family features | Men who meet current NHS genomic-testing criteria | Germline testing, tumour testing or both, depending on the clinical situation | May inform treatment decisions and identify inherited risk relevant to relatives |
| Understanding inherited risk | People with a known familial pathogenic variant, a qualifying personal or family history, or other features that meet current testing criteria | Risk assessment followed by blood or saliva testing where appropriate | May identify a pathogenic variant and support a more personalised risk assessment |
| Pre-test decision support | Individuals unsure about testing | Genetic counselling before proceeding | Helps you understand potential outcomes and implications |
| Impact on family members | Close relatives of someone with a pathogenic variant | Review of results with a specialist | Allows relatives to consider their own screening or testing |
| Planning future care | People with a confirmed pathogenic variant or recognised family risk | Review of appropriate monitoring options | Helps coordinate follow-up according to individual risk and current guidance |
What a Positive Genetic Test Result Means
A positive result usually means that a pathogenic or likely pathogenic genetic variant associated with increased cancer risk has been identified. It does not mean that you currently have prostate cancer or that you will definitely develop it. A variant of uncertain significance is different and should not normally be treated as proof of increased risk without specialist interpretation.
This information can be used to guide your ongoing care in a more personalised way. Depending on the gene involved, your family history, age and current guidance, you may be offered or advised to discuss risk-based surveillance with your healthcare team.
A positive result may also be relevant for your family members. It can give them the option to consider genetic testing and better understand their own risk. Sharing this information can support informed decisions about testing, screening and risk management across your family.
The Importance of Early Prostate Cancer Awareness
Being aware of your risk factors can help you decide when to discuss PSA testing, genetic assessment or monitoring with a healthcare professional. Prostate cancer often develops without noticeable symptoms in its early stages, which means it can go undetected for some time. This is why assessing your risk and discussing appropriate PSA testing or monitoring can be important.
For many men, early awareness can make a meaningful difference in how prostate health is monitored. A risk-based discussion with your GP or specialist can help determine whether PSA testing, genetic assessment or another form of follow-up is appropriate before symptoms develop. This allows for a more proactive and informed approach to your care.
If you are an Ashkenazi Jewish man with genetic or family risk factors, it is especially important to speak with a healthcare professional. Discussing PSA testing and appropriate follow-up may help identify clinically significant cancer earlier and support timely investigation and treatment decisions.
Understanding PSA Screening for Higher-Risk Men
The PSA (prostate-specific antigen) blood test is one of the main tools used to check for possible prostate problems. It measures the level of PSA in your blood, which can be higher when prostate cancer or other prostate conditions are present. While it is not a definitive test, it can help identify when further assessment may be needed.
PSA discussions are particularly relevant if you have recognised risk factors such as BRCA mutations, a strong family history of prostate cancer or other inherited cancer risks. Ashkenazi Jewish heritage may be relevant when considered alongside these factors.
If these risk factors apply to you, your doctor may suggest discussing PSA testing at an earlier age than would normally be considered for a man at average risk. The timing and frequency of testing will depend on your individual risk profile. A personalised approach helps ensure that monitoring is both appropriate and effective.
UK Guidance Note
Following its March 2026 review, the UK National Screening Committee recommended a targeted programme involving PSA testing every two years for men aged 45 to 61 who have a pathogenic BRCA2 variant and a family history of breast, ovarian, pancreatic or prostate cancer.
Ministers in England have agreed to implement this recommendation, with the nationally managed programme expected to begin rolling out in 2027. The pathway is still being developed. Screening policy is devolved, so implementation may differ in Scotland, Wales and Northern Ireland. Until then, ask your GP, genetics team or prostate specialist whether individual PSA testing or surveillance under existing clinical guidance is appropriate for you.
The UK NSC does not recommend population-wide prostate cancer screening or screening based on Ashkenazi Jewish ancestry alone. Men outside the recommended group can still discuss individual PSA testing with their GP or specialist, particularly if they have a strong family history or another recognised risk factor.
European guidance also recommends discussing early PSA testing from age 40 with well-informed BRCA2 carriers. This is broader than the current UK screening-programme recommendation, so your individual plan should be agreed with your healthcare team.
When Should Higher-Risk Men Discuss PSA Testing?
The appropriate time to discuss PSA testing depends on your specific risk factors rather than Ashkenazi Jewish ancestry alone. Genetic results, family history, age, life expectancy and general health should all be considered.
The March 2026 UK NSC recommendation identifies men aged 45 to 61 who have a pathogenic BRCA2 variant and a relevant family history as the group for whom PSA testing every two years should be introduced. Implementation arrangements for the national programme are still being developed. In the meantime, speak with your GP, genetics team or prostate specialist about whether individual PSA testing under existing clinical guidance is appropriate.
Talking about PSA testing early also gives you the chance to understand its benefits and limitations. You can explore what the results might mean and what steps could follow if anything unusual is found. This allows you to make informed decisions about your prostate health with confidence.
Why Early Detection Can Make a Difference
Finding clinically significant prostate cancer before it has spread may widen the available treatment options and improve the chances of successful disease management. For selected men whose risk is sufficiently high, structured PSA testing may therefore provide an overall benefit.
However, PSA testing can produce false-positive or false-negative results, lead to MRI or biopsy when cancer is not present and identify slow-growing cancers that would never have caused harm. Screening decisions should balance the possible benefit of earlier detection against overdiagnosis, biopsy risks and unnecessary treatment.
What Happens If Your PSA Level Is Elevated?
An elevated PSA level does not always mean you have prostate cancer. PSA can rise for several reasons, including an enlarged prostate, inflammation or an infection. A PSA result alone cannot diagnose prostate cancer.
If your PSA level is higher than expected, your doctor will look at the result in context. Factors such as your age, medical history and any symptoms will be considered before deciding on next steps. This helps ensure that any follow-up is appropriate for your situation.
You may be advised to have further assessments to understand the cause more clearly. Depending on your PSA result, symptoms, examination findings and overall risk, the next step may involve repeating the PSA test, referring you to a specialist or arranging multiparametric MRI. Not every raised PSA needs exactly the same investigation pathway. The aim is to build a clearer picture and decide whether any treatment or monitoring is needed.
The Role of MRI and Modern Prostate Cancer Assessment
Multiparametric MRI is an important diagnostic investigation, but it is not routinely used as a stand-alone screening test simply because you have Ashkenazi Jewish ancestry or a BRCA variant.
In the UK, MRI is usually considered after PSA results, examination findings or your overall risk suggest that clinically significant prostate cancer may be present. It can identify suspicious areas, help decide whether a biopsy is needed and guide targeted biopsy when appropriate.
MRI cannot detect every clinically significant prostate cancer. Your specialist will interpret the scan alongside your PSA level, PSA density, family history, genetic results and other clinical information.
How Genetic Information Can Influence Treatment Decisions
Genetic information is not only helpful for understanding your risk of developing prostate cancer. If you are diagnosed, these results can also play a role in shaping your treatment plan. This allows your care to be guided by more than just the diagnosis alone.
If you are diagnosed with prostate cancer, clinicians may consider both germline testing, which looks for inherited variants, and somatic testing, which looks for changes within the cancer itself. The appropriate test depends on the stage and characteristics of your disease.
In adults with metastatic castration-resistant prostate cancer and a BRCA1 or BRCA2 mutation, olaparib may be an option when the cancer has progressed after treatment with a newer hormonal medicine such as abiraterone or enzalutamide. Eligibility also depends on previous treatment, overall health, licensing requirements and current NICE guidance.
Prostate Cancer Risk Is Not Determined by Genetics Alone
Genetics is only one part of prostate cancer risk. Age, family history, ethnicity and inherited pathogenic variants are established risk factors. Body weight may be associated with the risk of advanced disease, while healthy habits primarily support general health rather than remove inherited risk. Genetic information can support more personalised healthcare decisions, but it cannot predict with certainty whether an individual will develop prostate cancer.
The Importance of Genetic Counselling Before Testing
Genetic testing can provide valuable insights, but understanding what the results mean is just as important. Genetic counselling helps you prepare for what a test may reveal and how it could influence your health decisions. It also explains what the findings may mean for your family members. This support can help you approach testing with greater clarity and realistic expectations.
- Understanding results: Helps you interpret what a positive, negative or uncertain result means for your health and future risk.
- Risk versus diagnosis: Explains the difference between carrying a pathogenic variant and having cancer, reducing unnecessary fear or confusion.
- Family implications: Outlines how your results may affect close relatives and whether they should consider testing or screening.
- Emotional support: Prepares you for the possible psychological impact of learning about your genetic risk.
- Decision guidance: Supports you in deciding whether to proceed with testing and what steps to take afterwards.
A trained professional can guide you through each stage of the process with clear and balanced information. This makes it easier to understand complex genetic concepts without feeling overwhelmed. You are given space to ask questions and consider your options carefully. With the right guidance, you can make informed decisions that feel right for you and your family.
How Genetic Testing May Help Your Family Members
If you are found to carry an inherited gene change such as a BRCA mutation, it may have implications beyond your own health. Your close relatives could also carry the same variant, which means they may want to consider whether testing is appropriate for them. This creates an opportunity for shared awareness within your family.
Understanding a possible inherited risk can help your family members make informed decisions about their health. Relatives may be offered genetic counselling, testing and cancer-specific risk-management options based on their age, sex, result and family history. Having this knowledge allows you to plan ahead rather than react later.
It can also open up important conversations within your family about health history and future care. While these discussions can feel sensitive, they often lead to better preparedness and reassurance over time. With the right guidance, you can approach these decisions in a clear and supportive way.
Lifestyle Factors and Prostate Health
Lifestyle changes cannot remove inherited risk or guarantee that prostate cancer will be prevented. However, maintaining a healthy weight, remaining physically active, avoiding smoking and following a balanced diet can support your general health and wellbeing.
Continue any risk-based testing or follow-up agreed with your GP, genetics team or prostate specialist, and discuss any new symptoms or concerns with your healthcare team.
Top of Form
Bottom of Form
How Advances in Research Are Improving Personalised Care
Research is improving how inherited and tumour genetic information is used to assess risk, investigate suspected cancer and select treatment. These developments are supporting more individualised care, although not every genetic finding currently changes screening or treatment.
Clinical evidence supports genetically guided treatments for selected patients with metastatic castration-resistant prostate cancer, while other treatment combinations, screening approaches and biomarkers remain under investigation. Your specialist can explain which options are established treatments and which are available only through research or clinical trials.
Myth vs Fact
| Myth | Fact |
| Being Ashkenazi Jewish means you will develop prostate cancer. | Ashkenazi Jewish heritage can be associated with a higher likelihood of certain inherited genetic variants, but it does not mean you will definitely develop prostate cancer. |
| Only women need to worry about BRCA mutations. | BRCA mutations can affect men as well. Certain inherited changes, particularly BRCA2 mutations, are linked with an increased risk of prostate cancer. |
| Genetic testing can tell you whether you definitely have cancer. | Genetic testing identifies inherited changes that may increase cancer risk. It does not diagnose prostate cancer or predict your future with certainty. |
| If you have no family history of cancer, you do not need to consider genetic risk. | A family history can increase suspicion of inherited risk, but some inherited genetic changes may occur even when there is no obvious family history of cancer. |
| A high PSA level always means you have prostate cancer. | PSA can increase for several reasons, including benign prostate enlargement, inflammation or infection. Further assessment is often needed before reaching a diagnosis. |
| Screening decisions are the same for every man. | Prostate cancer screening decisions should be personalised based on factors such as age, family history, genetic risk and overall health. |
| Finding a BRCA mutation means prostate cancer is inevitable. | A BRCA mutation increases risk but does not guarantee that cancer will develop. It provides information that can help guide monitoring and healthcare decisions. |
Key Takeaways
- Ashkenazi Jewish heritage does not mean you will develop prostate cancer, but certain inherited genetic variants may increase your risk.
- Pathogenic BRCA2 variants are particularly important when assessing inherited prostate cancer risk because they are associated with a higher likelihood of developing clinically significant or aggressive disease.
- A family history of prostate, breast, ovarian or pancreatic cancer may indicate that genetic assessment could be beneficial.
- Genetic testing and counselling can help you understand inherited risk and guide personalised decisions about screening and monitoring.
- PSA testing should not be based on heritage alone. Your age, family history, genetic results and overall health should all be considered.
- Early discussions with your doctor can help you understand your risk and decide whether genetic testing or earlier prostate monitoring may be appropriate.
- The UK NSC has recommended PSA testing every two years from ages 45 to 61 for men with a pathogenic BRCA2 variant and a relevant family history. In England, national rollout is expected to begin in 2027.
Frequently Asked Questions
1. Does being Ashkenazi Jewish mean you will get prostate cancer?
No. Your ancestry may increase the likelihood that you carry a harmful BRCA variant, but it does not determine whether you will develop prostate cancer. Many Ashkenazi Jewish men do not carry a harmful BRCA variant, and many never develop prostate cancer. Understanding your individual risk can help you make informed decisions about testing and monitoring.
2. Why may some Ashkenazi Jewish men have increased genetic risk?
Your genetic background may include certain inherited variants, sometimes called founder variants, that are more common in this population. These can affect how your cells repair DNA and may increase cancer risk. However, not everyone carries these variants. Even if you do, it does not guarantee that cancer will develop.
3. Should you consider genetic testing?
You may consider genetic testing if you have a strong family history of prostate, breast, ovarian or pancreatic cancer, or if a relative has a confirmed pathogenic BRCA variant. As of July 2026, the NHS Jewish BRCA Testing Programme is closed to new registrations following completion of its pilot. A longer-term NHS service is anticipated to open for new registrations in 2027. In the meantime, speak with your GP or genetics service because you may qualify through another NHS testing pathway.
4. What does a pathogenic BRCA variant mean for you?
If you carry a pathogenic BRCA2 variant, your risk of developing prostate cancer may be higher than average, and cancers that develop may be more likely to be clinically significant or aggressive. The association between BRCA1 and prostate cancer is less clear, so any result should be interpreted with your genetics or prostate specialist. A pathogenic variant increases risk but does not mean that you will definitely develop cancer.
5. When should you start PSA screening if you are higher risk?
The UK NSC has recommended PSA testing every two years from ages 45 to 61 for men with a pathogenic BRCA2 variant and a relevant family history. The nationally managed programme is expected to begin rolling out in England in 2027. Separately, European guidance recommends discussing individual early PSA testing from age 40 with well-informed BRCA2 carriers. Your plan should be agreed with your healthcare team because Ashkenazi Jewish ancestry alone does not determine when testing should begin.
6. Can you have prostate cancer without symptoms?
Yes. Early prostate cancer often causes no noticeable symptoms, so you may feel well even when cancer is present. If you have a pathogenic BRCA2 variant or a relevant family history, discuss your risk and the potential benefits and limitations of PSA testing with your healthcare team.
7. What should you do if your PSA level is high?
A raised PSA level does not automatically mean you have prostate cancer. It can also be caused by non-cancerous conditions such as an enlarged prostate or inflammation. Your doctor may repeat the PSA test or recommend further assessment, depending on the result, your symptoms and your overall risk. Further assessment may include specialist referral, multiparametric MRI or other investigations.
8. How does family history affect your risk?
If your father, brother or other close relatives have had prostate cancer, your risk may be higher. Patterns of related cancers, including breast, ovarian or pancreatic cancer, can also suggest an inherited risk. Sharing this information with your doctor is important. It helps guide decisions about testing and screening.
9. Can genetic results affect your treatment options?
Yes. If you are diagnosed with prostate cancer, inherited variants or genetic changes within the tumour may influence your treatment options. In adults with metastatic castration-resistant prostate cancer and a BRCA1 or BRCA2 mutation, olaparib may be an option when the cancer has progressed after treatment with a newer hormonal medicine such as abiraterone or enzalutamide. Eligibility also depends on previous treatment, overall health, licensing requirements and current NICE guidance.
10. What is the best step you can take right now?
You should consider speaking with your doctor about your personal and family history. This can help determine whether genetic testing or earlier screening is appropriate for you. Taking action early does not mean expecting the worst. It can help you obtain the information needed to make informed decisions about your health.
Final Thoughts: Taking Control of Your Prostate Health
Understanding how your Ashkenazi Jewish heritage may influence prostate cancer risk can help you make more informed decisions about your health. While genetic factors such as BRCA mutations can increase risk, they do not determine your future. Instead, they offer an opportunity to take a more personalised and proactive approach to screening, monitoring and care.
By documenting your family history, considering genetic testing where appropriate and discussing current PSA guidance with a healthcare professional, you can develop a plan based on your individual risk. Genetic testing and PSA monitoring cannot prevent prostate cancer or guarantee that it will be detected early, but they can support better-informed decisions about your care.
If you want expert assessment for prostate symptoms, PSA changes or treatment options, you can contact Prostate Clinic London to discuss your first appointment and next steps.
References:
- Castro, E. et al. (2013) ‘Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer’, Journal of Clinical Oncology, 31(14), pp. 1748–1757. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3641696/
- Pritchard, C.C. et al. (2016) ‘Inherited DNA-repair gene mutations in men with metastatic prostate cancer’, New England Journal of Medicine, 375, pp. 443–453. Available at: https://pubmed.ncbi.nlm.nih.gov/27433846/
- National Cancer Institute (NCI) (2024) BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet. Available at: https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet
- UK National Screening Committee (2026) Prostate cancer: UK NSC screening recommendation. Available at: https://view-health-screening-recommendations.service.gov.uk/prostate-cancer/
- GOV.UK (2026) Equality impact assessment: introduction of a targeted prostate cancer screening programme. Available at: https://www.gov.uk/government/publications/prostate-cancer-screening-equality-impact-assessment/equality-impact-assessment-introduction-of-a-targeted-prostate-cancer-screening-programme
- NHS (2025) Genetic tests to check your cancer risk. Available at: https://www.nhs.uk/tests-and-treatments/genetic-tests-for-cancer-risk/
- NHS England (2025) Hundreds of people at increased cancer risk identified by new NHS BRCA testing programme. Available at: https://www.england.nhs.uk/2025/01/hundreds-of-people-at-increased-cancer-risk-identified-by-new-nhs-brca-testing-programme/
- European Association of Urology (2026) EAU Guidelines on Prostate Cancer: Diagnostic Evaluation. Arnhem: EAU Guidelines Office. Available at: https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation
- Mateo, J. et al. (2024) ‘Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and/or BRCA2 in the PROfound trial’, Journal of Clinical Oncology, 42(5), pp. 571–583. Available at: https://pubmed.ncbi.nlm.nih.gov/37963304/
- Bancroft, E.K. et al. (2026) ‘Targeted prostate cancer screening in carriers of BRCA1 or BRCA2 pathogenic germline variants detects clinically relevant disease: 5-year results from the IMPACT study’, European Urology, 89(5), pp. 457–468. Available at: https://pubmed.ncbi.nlm.nih.gov/41714267/
- GOV.UK (2026) Major expansion of research and treatment for prostate cancer. Available at: https://www.gov.uk/government/news/major-expansion-of-research-and-treatment-for-prostate-cancer